Insulin aspart

Generic Name
Insulin aspart
Brand Names
Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
Drug Type
Biotech
Chemical Formula
-
CAS Number
116094-23-6
Unique Ingredient Identifier
D933668QVX
Background

Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...

Indication

Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.

Associated Conditions
Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
Associated Therapies
-

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

First Posted Date
2007-07-25
Last Posted Date
2019-01-08
Lead Sponsor
University of Texas Southwestern Medical Center
Registration Number
NCT00505882
Locations
🇺🇸

UT Southwestern at Dallas, Dallas, Texas, United States

Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes

Phase 3
Completed
Conditions
First Posted Date
2007-07-20
Last Posted Date
2023-11-02
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
277
Registration Number
NCT00504673

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2007-07-12
Last Posted Date
2015-06-03
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
52
Registration Number
NCT00500240
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart

Phase 4
Completed
Conditions
First Posted Date
2007-07-02
Last Posted Date
2016-03-04
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
33
Registration Number
NCT00494988

Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes

First Posted Date
2007-05-16
Last Posted Date
2017-03-10
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
470
Registration Number
NCT00474045
Locations
🇬🇧

Novo Nordisk Investigational Site, Watford, United Kingdom

Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)

First Posted Date
2007-05-14
Last Posted Date
2017-03-01
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
38
Registration Number
NCT00472953
Locations
🇹🇷

Novo Nordisk Investigational Site, Kocaeli, Turkey

Comparison of Insulins Aspart and Lispro in Insulin Pumps

First Posted Date
2007-04-18
Last Posted Date
2021-01-08
Lead Sponsor
Tulane University Health Sciences Center
Target Recruit Count
20
Registration Number
NCT00461331
Locations
🇺🇸

Clinical Translational Unit - Tulane School of Medicine, New Orleans, Louisiana, United States

Changes of the Infusion Rate in Insulin Pump Treatment

Phase 4
Completed
Conditions
Interventions
First Posted Date
2007-03-21
Last Posted Date
2009-07-02
Lead Sponsor
Aarhus University Hospital
Target Recruit Count
10
Registration Number
NCT00449839
Locations
🇩🇰

Aarhus University Hospital, department of Endocrinology and Diabetes, Aarhus C, Aarhus, Denmark

Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes

First Posted Date
2007-03-14
Last Posted Date
2024-01-02
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
330
Registration Number
NCT00447382

Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes

First Posted Date
2007-02-14
Last Posted Date
2017-03-10
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
348
Registration Number
NCT00435019
Locations
🇬🇧

Novo Nordisk Investigational Site, Norfolk, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath